LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) announced Thursday plans to place its LX Analyzer beta unit into ProVerde Laboratories Inc, one of the largest hemp-cannabis testing reference laboratories in Massachusetts.
ProVerde Laboratories is one of three independent laboratories accredited by the state of Massachusetts to test hemp and cannabis products for contaminants such as pesticides and pathogens, including bacteria, mold, or other dangerous microorganisms, according to a statement.
LexaGene’s LX Analyzer is designed to test a variety of sample types for harmful pathogens that cause adverse reactions in humans and animals.
ProVerde currently cultures samples overnight, followed by processing steps that include using an automated single-target immunoassay analyzer to identify pathogenic organisms, as well as starting a second culture to enumerate indicator species.
The process nominally takes three days, and ProVerde is looking for faster turnaround times. For this reason, ProVerde is interested in testing LexaGene’s analyzer, which is designed to screen for multiple pathogenic organisms at once and provide quantitation of indicator organisms in just one hour.
For the beta test trial, which is scheduled to start next week, ProVerde will use LexaGene’s genetic analyzer to detect and quantify pathogenic E. coli, Salmonella, and the toxic fungus, Aspergillus niger.
Dr Christopher Hudalla, ProVerde’s founder and chief scientific officer, praised LexaGene for “promoting the benefits of uniform testing requirements,” which vary from state to state in the US.
“Over the past several years, we have worked with a number of innovative companies to help them develop, refine and validate their equipment, processes and products for the cannabis and hemp testing markets,” Hudalla said.
“It’s exciting to work with LexaGene and their new rapid detection platform which has the potential to make an impact on the testing demands of these industries.”
As the use of cannabis and hemp products for medicinal purposes increases, Massachusetts-based LexaGene said it sees an opportunity to provide its open-access instrument for use in testing laboratories to enable screening for pathogens that affect human health.
“This is now our second beta placement in a hemp-cannabis testing reference laboratory,” said Dr Jack Regan, LexaGene’s CEO and founder.
“We strongly believe the LX technology will be revolutionary for the hemp and cannabis industry as it will help prevent the spread of disease and can be used to ensure safer products for consumption.”
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham